Related Experiment Video

Updated: Feb 4, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Current Status of Inotropes in Heart Failure

Mahazarin Ginwalla1, David S Tofovic1

  • 1Division of Cardiovascular Medicine, Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Heart Failure Clinics
|September 30, 2018
PubMed

Insights

Inotropes enhance heart contractility for patients with low cardiac output. This review covers their history, benefits, risks, and current guidelines for heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Inotropes are vital medications for improving cardiac contractility.
  • They are prescribed for patients experiencing low cardiac output or end-organ dysfunction.

Purpose of the Study:

  • To provide a comprehensive overview of inotropes in heart failure management.
  • To discuss the historical context, mechanisms, and clinical application of inotropes.

Main Methods:

  • Literature review of inotropes in heart failure.
  • Analysis of historical data, clinical trials, and current guidelines.
  • Discussion of practical aspects and limitations of inotrope therapy.

Main Results:

  • Inotropes offer symptomatic relief and potential longevity benefits.
  • Decades of research have clarified both the advantages and disadvantages of inotropes.
  • Current guidelines address appropriate use, though challenges remain.

Conclusions:

  • Inotropes play a significant role in managing heart failure patients with impaired contractility.
  • Understanding their appropriate use, risks, and practical considerations is crucial for effective patient care.
  • This review synthesizes current knowledge on inotropes for clinicians treating heart failure.
Keywords:
CardiogenicDobutamineDopamineHeart failureInotropesMilrinonePalliative careShock

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981